Willow Biosciences Inc.

TSX:WLLW Stock Report

Market Cap: CA$8.7m

Willow Biosciences Management

Management criteria checks 2/4

Willow Biosciences' CEO is Chris Savile, appointed in Mar 2023, has a tenure of 1.75 years. directly owns 0.94% of the company’s shares, worth CA$81.74K. The average tenure of the management team and the board of directors is 5.7 years and 1.8 years respectively.

Key information

Chris Savile

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownership0.9%
Management average tenure5.7yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

Dec 20
We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

Sep 02
We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

May 20
We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

Jan 19
Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

CEO Compensation Analysis

How has Chris Savile's remuneration changed compared to Willow Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$8m

Jun 30 2024n/an/a

-CA$9m

Mar 31 2024n/an/a

-CA$11m

Dec 31 2023n/an/a

-CA$13m

Sep 30 2023n/an/a

-CA$15m

Jun 30 2023n/an/a

-CA$17m

Mar 31 2023n/an/a

-CA$17m

Dec 31 2022CA$584kCA$358k

-CA$15m

Sep 30 2022n/an/a

-CA$15m

Jun 30 2022n/an/a

-CA$7m

Mar 31 2022n/an/a

CA$2m

Dec 31 2021CA$749kCA$297k

-CA$6m

Sep 30 2021n/an/a

-CA$16m

Jun 30 2021n/an/a

-CA$27m

Mar 31 2021n/an/a

-CA$44m

Dec 31 2020CA$447kCA$297k

-CA$34m

Sep 30 2020n/an/a

-CA$22m

Jun 30 2020n/an/a

-CA$16m

Mar 31 2020n/an/a

-CA$45m

Dec 31 2019CA$789kCA$209k

-CA$45m

Compensation vs Market: Insufficient data to establish whether Chris's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Savile

1.8yrs

Tenure

CA$584,324

Compensation

Dr. Chris Savile serves as President and Chief Executive Officer Willow Biosciences Inc. since March 28, 2023. He served as its Chief Operations Officer since April 7, 2020 until 2023. Dr. Savile served as...

Leadership Team

NamePositionTenureCompensationOwnership
Travis Doupe
Chief Financial Officer5.7yrsCA$376.55k1.07%
CA$ 92.8k
Chris Savile
President1.8yrsCA$584.32k0.94%
CA$ 81.7k
Sanjib Gill
Corporate Secretary5.7yrsno datano data

5.7yrs

Average Tenure

Experienced Management: WLLW's management team is seasoned and experienced (5.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chris Savile
President1.8yrsCA$584.32k0.94%
CA$ 81.7k
Donald Archibald
Independent Director5.7yrsCA$95.25k1.3%
CA$ 112.1k
James Lalonde
Independent Chairman1.8yrsCA$68.14k0.27%
CA$ 23.2k
Albert Foreman
Director5.7yrsCA$91.50k0.049%
CA$ 4.3k
Raffi Asadorian
Independent Director1.6yrsCA$48.30k0.0046%
CA$ 399.7

1.8yrs

Average Tenure

59yo

Average Age

Experienced Board: WLLW's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 18:33
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Willow Biosciences Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David KideckelATB Capital Markets